二肽基肽酶 (Dipeptidyl Peptidase) 是广泛分布的外肽酶,在蛋白水解中起着核心作用。二肽基肽酶家族包括 DPP-IV DPP7、DPP8、DPP9、成纤维细胞活化蛋白等,它们在倒数第二个脯氨酸残基后切割肽键,并且富含药物靶标。
DPP-IV(DPP4 或 CD26)是一种丝氨酸蛋白酶,可在多种免疫细胞和各种器官的上皮细胞中检测到。除了膜结合酶外,在多种体液中还检测到具有催化活性的可溶形式。两种变体均可从各种趋化因子、神经肽和激素的 N 端切割二肽。DPP IV 通过靶向不同的底物在免疫调节、炎症、氧化应激、细胞粘附和细胞凋亡中发挥关键作用。DPP IV 抑制剂通常用作降血糖药。
DPP8 和 DPP9 表现出类似 DPPIV 的活性,并且彼此具有非常高的序列相似性。DPP8 和 DPP9 是细胞内 N 端二肽基肽酶(优先为脯氨酸后),与免疫反应和癌症生物学中的病理生理作用有关。
Dipeptidyl Peptidases are widely distributed exopeptidases that possess central role in proteolysis. The dipeptidyl peptidase family, including DPP-IV DPP7, DPP8, DPP9, fibroblast activation protein and others, cleave the peptide bond after the penultimate proline residue and are drug target rich.
DPP-IV (DPP4 or CD26) is a serine protease detected on several immune cells and on epithelial cells of various organs. Besides the membrane-bound enzyme, a catalytically active soluble form is detected in several body fluids. Both variants cleave off dipeptides from the N-termini of various chemokines, neuropeptides, and hormones. DPP IV plays a key role in immune-regulation, inflammation, oxidative stress, cell adhesion, and apoptosis by targeting different substrates. DPP IV inhibitors are commonly used as hypoglycemic agents.
DPP8 and DPP9 show DPPIV-like activity and share a very high-sequence similarity to each other. DPP8 and DPP9 are intracellular N-terminal dipeptidyl peptidases (preferentially postproline) associated with pathophysiological roles in immune response and cancer biology.
(2R)-Vildagliptin 是 Vildagliptin (MS-K54451) 的异构体,可作为实验中的对照化合物,而 Vildagliptin (LAF237) 是一种有效且稳定的选择性二肽基肽酶IV (DPP-IV) 抑制剂,在人 Caco-2 细胞中抑制 DPP-IV 的 IC50 为 3.5 nM,具有出色的口服生物利用度和有效的降血糖活性。
H-Pro-Val-OH 是一种含脯氨酸的去质子化二肽,能催化丙酮对反式硝基苯乙烯的迈克尔加成反应,也可作为纤维母细胞酶和脯氨酸酶的底物,在生化分析中有潜在应用。
Linagliptin methyldimer 是 Linagliptin 的一种杂质,而 Linagliptin 是一种 DPP-IV 抑制剂,其 IC50 值为 1 nM。
(–)-Sitagliptin carbamoyl glucuronide 是二肽基肽酶 4 (DPP-4) 抑制剂 Sitagliptin (MS-M62474) 的次级代谢物。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号